Acalabrutinib plus Obinutuzumab in Treatment-Naive and Relapsed/Refractory Chronic Lymphocytic Leukemia
- 1 March 2020
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 10 (3), 394-405
- https://doi.org/10.1158/2159-8290.CD-19-1130
Abstract
Acalabrutinib is a selective irreversible Bruton tyrosine kinase (BTK) inhibitor that does not affect IL2-associated tyrosine kinase or antibody-dependent cellular cytotoxicity, making it an attractive candidate for combination therapy with anti-CD20 antibodies. We investigated acalabrutinib plus obinutuzumab in a phase Ib/II study (NCT02296918) of patients with treatment-naive or relapsed/refractory chronic lymphocytic leukemia (CLL). Nineteen treatment-naive and 26 relapsed/refractory patients were treated with acalabrutinib (100 mg twice daily) until progression and obinutuzumab (cycle 1: 100 mg day 1, 900 mg day 2, 1000 mg days 8 and 15; cycles 2-6: 1,000 mg day 1). Grade 3/4 adverse events occurred in 71% of patients. Overall response rates were 95% (treatment-naive) and 92% (relapsed/refractory). Thirty-two percent of treatment-naive and 8% of relapsed/refractory patients achieved complete remission. At 36 months, 94% (treatment-naive) and 88% (relapsed/refractory) were progression free. Acalabrutinib plus obinutuzumab was well tolerated, producing high and durable responses in treatment-naive and relapsed/refractory CLL. SIGNIFICANCE: Rituximab plus the less selective BTK inhibitor ibrutinib has not shown benefit in CLL; however, the selective BTK inhibitor acalabrutinib plus the antibody-dependent cellular cytotoxicity-enhanced antibody obinutuzumab yielded durable responses that deepened over time in treatment-naive and relapsed/refractory CLL, supporting the evaluation of this approach in larger, comparative studies in CLL.Other Versions
Funding Information
- NIH (P30 CA016058, R01 CA197870)
- NIH (R35 CA198183)
- Leukemia and Lymphoma Society
- Ohio State University
This publication has 31 references indexed in Scilit:
- Comparative Assessment of Clinically Utilized CD20-Directed Antibodies in Chronic Lymphocytic Leukemia Cells Reveals Divergent NK Cell, Monocyte, and Macrophage PropertiesPublished by The American Association of Immunologists ,2013
- The clinically active BTK inhibitor PCI-32765 targets B-cell receptor– and chemokine-controlled adhesion and migration in chronic lymphocytic leukemiaBlood, 2012
- Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765Blood, 2011
- Mechanism of Action of Type II, Glycoengineered, Anti-CD20 Monoclonal Antibody GA101 in B-Chronic Lymphocytic Leukemia Whole Blood Assays in Comparison with Rituximab and AlemtuzumabThe Journal of Immunology, 2011
- Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelinesBlood, 2008
- Health-Related Quality of Life in Younger Patients With Chronic Lymphocytic Leukemia Treated With Fludarabine Plus Cyclophosphamide or Fludarabine Alone for First-Line Therapy: A Study by the German CLL Study GroupJournal of Clinical Oncology, 2007
- International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemiaLeukemia, 2007
- Bruton's Tyrosine Kinase and Phospholipase Cγ2 Mediate Chemokine-Controlled B Cell Migration and HomingImmunity, 2007
- The health status and quality of life of adults with X-linked agammaglobulinemiaClinical Immunology, 2006
- Quality of life of patients with chronic lymphocytic leukemia: results of a longitudinal investigation over 1 yrEuropean Journal of Haematology, 2004